Literature DB >> 26679755

Using intron splicing trick for preferential gene expression in transduced cells: an approach for suicide gene therapy.

F Pourzadegan1, L Shariati2, R Taghizadeh1, H Khanahmad1,3, Z Mohammadi1, M A Tabatabaiefar1,3.   

Abstract

Suicide gene therapy is one of the most innovative approaches in which a potential toxic gene is delivered to the targeted cancer cell by different target delivery methods. We constructed a transfer vector to express green fluorescent protein (GFP) in transduced cells but not in packaging cells. We placed gfp under the control of the cytomegalovirus (CMV) promoter, which is positioned between the two long-terminal repeats in reverse direction. The intron-2 sequence of the human beta globin gene with two poly-A signals and several stop codons on the antisense strand was placed on the leading strand between the CMV promoter and gfp. For lentiviral production, the HEK293T and line were co-transfected with the PMD2G, psPAX2 and pLentiGFP-Ins2 plasmids. The HEK293T and line were transduced with this virus. PCR was performed for evaluation of intron splicing in transduced cells. The GFP expression was seen in 65% of the cells transduced. The PCR amplification of the genomic DNA of transduced cells confirmed the splicing of intron 2. The strategy is significant to accomplish our goal for preserving the packaging cells from the toxic gene expression during viral assembly and the resultant reduction in viral titration. Also it serves to address several other issues in the gene therapy.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26679755     DOI: 10.1038/cgt.2015.57

Source DB:  PubMed          Journal:  Cancer Gene Ther        ISSN: 0929-1903            Impact factor:   5.987


  25 in total

Review 1.  Prodrug-activating systems in suicide gene therapy.

Authors:  C J Springer; I Niculescu-Duvaz
Journal:  J Clin Invest       Date:  2000-05       Impact factor: 14.808

2.  Gene therapy, early promises, subsequent problems, and recent breakthroughs.

Authors:  Saeideh Razi Soofiyani; Behzad Baradaran; Farzaneh Lotfipour; Tohid Kazemi; Leila Mohammadnejad
Journal:  Adv Pharm Bull       Date:  2013-08-20

3.  Suicide cancer gene therapy using pore-forming toxin, streptolysin O.

Authors:  Wan Seok Yang; Sue-O Park; A-Rum Yoon; Ji Young Yoo; Min Kyung Kim; Chae-Ok Yun; Chul-Woo Kim
Journal:  Mol Cancer Ther       Date:  2006-06       Impact factor: 6.261

Review 4.  Gene therapy clinical trials worldwide to 2012 - an update.

Authors:  Samantha L Ginn; Ian E Alexander; Michael L Edelstein; Mohammad R Abedi; Jo Wixon
Journal:  J Gene Med       Date:  2013-02       Impact factor: 4.565

5.  Tetracycline-controlled expression but not toxicity of an attenuated diphtheria toxin mutant.

Authors:  K Keyvani; I Baur; W Paulus
Journal:  Life Sci       Date:  1999       Impact factor: 5.037

6.  Prostate-specific expression of the diphtheria toxin A chain (DT-A): studies of inducibility and specificity of expression of prostate-specific antigen promoter-driven DT-A adenoviral-mediated gene transfer.

Authors:  Ying Li; John McCadden; Fernando Ferrer; Mark Kruszewski; Michael Carducci; Jonathan Simons; Ronald Rodriguez
Journal:  Cancer Res       Date:  2002-05-01       Impact factor: 12.701

7.  Regulated expression of the diphtheria toxin A chain by a tumor-specific chimeric transcription factor results in selective toxicity for alveolar rhabdomyosarcoma cells.

Authors:  E S Massuda; E J Dunphy; R A Redman; J J Schreiber; L E Nauta; F G Barr; I H Maxwell; T P Cripe
Journal:  Proc Natl Acad Sci U S A       Date:  1997-12-23       Impact factor: 11.205

8.  Novel cytotoxic vectors based on adeno-associated virus.

Authors:  Johannes Kohlschütter; Stefan Michelfelder; Martin Trepel
Journal:  Toxins (Basel)       Date:  2010-12-01       Impact factor: 4.546

9.  Exploiting the Intron-splicing Mechanism of Insect Cells to Produce Viral Vectors Harboring Toxic Genes for Suicide Gene Therapy.

Authors:  Haifeng Chen
Journal:  Mol Ther Nucleic Acids       Date:  2012-11-27       Impact factor: 10.183

Review 10.  Newer gene editing technologies toward HIV gene therapy.

Authors:  N Manjunath; Guohua Yi; Ying Dang; Premlata Shankar
Journal:  Viruses       Date:  2013-11-14       Impact factor: 5.048

View more
  2 in total

1.  Combination of MPPa-PDT and HSV1-TK/GCV gene therapy on prostate cancer.

Authors:  Liming Liang; Wenxiang Bi; Weiwen Chen; Yani Lin; Yuanyuan Tian
Journal:  Lasers Med Sci       Date:  2018-01-06       Impact factor: 3.161

2.  A small, portable RNA device for the control of exon skipping in mammalian cells.

Authors:  Marc Vogel; Julia E Weigand; Britta Kluge; Manuel Grez; Beatrix Suess
Journal:  Nucleic Acids Res       Date:  2018-05-04       Impact factor: 16.971

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.